Latest Otsuka Holdings Co. (OTSKY) Headlines
Post# of 4
Posted On: 03/10/2014 10:31:43 PM
Latest Otsuka Holdings Co. (OTSKY) Headlines
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Schizophrenia Global Clinical Trials Review, 2013 Contains Essential Data for those in the Psychiatry Field
M2 - Thu Nov 21, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/pphskq/schizophrenia) has announced the addition of the "Schizophrenia Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizophrenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizophrenia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated). Companies Mentioned: - Johnson & Johnson - Pfizer Inc. - AstraZeneca PLC - Eli Lilly and Company - Otsuka Holdings Co., Ltd. - Sumitomo Chemical Company, Limited - Merck & Co., Inc. - Bristol-Myers Squibb Company - H. Lundbeck A/S - AbbVie Inc. - The University of Maryland - Yale University For more information visit http://www.researchandmarkets.com/research/pp...izophrenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Peptic Ulcers Global Clinical Trials Review, H2, 2013 Features the Key Drugs for Treating Peptic Ulcers
M2 - Wed Nov 20, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/p6twhl/peptic_ulcers) has announced the addition of the "Peptic Ulcers Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Peptic Ulcers Global Clinical Trials Review, H2, 2013" provides data on the Peptic Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peptic Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peptic Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Clinical Trial Overview of Takeda Pharmaceutical Company Limited - Pozen, Inc. - Clinical Trial Overview of Pozen, Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Zuventus Healthcare Ltd - Zeria Pharmaceutical Co Ltd - Otsuka Holdings Co., Ltd. - Eisai Co., Ltd. - Daiichi Sankyo Company, Limited - Chinese University of Hong Kong - Department of Health, South Africa - National Taiwan University Hospital - The Catholic University of Korea - Yokohama City University - Odense University Hospital - University of California, San Francisco - Keio University - Hamamatsu University School of Medicine - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/p6...tic_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
United States Supplement Market to 2016
M2 - Fri Oct 25, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rq7rxm/supplement_market) has announced the addition of the "United States Supplement Market to 2016" report to their offering. One of the main trends witnessed in the Supplement market in the US is the availability of supplement in alternate forms. Natural nutrients such as protein, vitamin, minerals, enzymes, and herbs and botanicals are important ingredients of the regular diet of a person. Proper consumption of these nutrients is essential for maintaining a healthy life. However, the presence of some adverse environmental factors, such as unhealthy diet and sedentary lifestyle are leading to malnutrition. Thus, with the introduction of supplement-based products, people are able to cope with these deficiencies. Vendors are providing supplement products in different forms such as instant health drinks, chocolate bars, probiotic drinks, pediatric nutrient products, adult nutrient products, and vitamin water. According to the report, one of the main factors driving the market is the increased focus on organic healthcare products. Organic healthcare products they are helpful in the treatment of diseases such cardiovascular, neurological diseases, and macular degeneration; effective against age-related muscular degeneration, and relieving cold and flu symptoms, which is in turn increasing demand for the same. Further, the report states that one of the main challenges is the negative publicity by media. But overly negative publicity against some of the supplement-based products by electronics media and print media is affecting consumer perception toward the supplement-based products. The key vendors dominating this space include: - Abbott Laboratories Inc. - GNC Holdings Inc. - NBTY Inc. - Otsuka Holdings Co. Ltd. - Perrigo Co. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology 05. Scope of the Report 06. Market Landscape 07. Vendor Landscape 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rq...ent_market
Global Hyponatremia Clinical Trials Review Report, H2 2013 Edition
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2njzf6/hyponatremia) has announced the addition of the "Hyponatremia Global Clinical Trials Review, H2, 2013" report to their offering. Hyponatremia Global Clinical Trials Review, H2, 2013" provides data on the Hyponatremia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyponatremia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyponatremia. Reasons to Buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hyponatremia Therapeutics Clinical Trials - Astellas Pharma Inc. - Cardiokine, Inc. - Otsuka Pharmaceutical Co., Ltd. - Sanofi - Otsuka Holdings Co., Ltd. - Otsuka Pharmaceutical Development & Commercialization, Inc. - Otsuka Maryland Medicinal Laboratories, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Zydus Cadila Healthcare Limited - Ranbaxy Laboratories Limited For more information visit http://www.researchandmarkets.com/research/2n...ponatremia
Otsuka Pharmaceutical Co Ltd acquires Astex Pharmaceuticals for USD8.50 per share
M2 - Mon Oct 14, 5:50AM CDT
Otsuka Holdings Co Ltd reported on Friday the completion of the acquisition of Astex Pharmaceuticals Inc (NasdaqGS:ASTX) for USD8.50 per share, net to the seller in cash, without interest and less any required withholding taxes.
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
Business Wire - Fri Oct 11, 7:31AM CDT
Otsuka Holdings Co., Ltd. ("Otsuka Holdings") announced today that its wholly-owned subsidiary, Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), successfully completed, through its wholly-owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") for US $8.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The acquisition was effected through a tender offer ("Tender Offer"), which was commenced on September 13, 2013, New York time and expired at 12:00 midnight, New York time at the end of October 10, 2013, followed by a merger on October 11, 2013.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"), concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka"). Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.
Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Schizophrenia Global Clinical Trials Review, 2013 Contains Essential Data for those in the Psychiatry Field
M2 - Thu Nov 21, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/pphskq/schizophrenia) has announced the addition of the "Schizophrenia Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizophrenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizophrenia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated). Companies Mentioned: - Johnson & Johnson - Pfizer Inc. - AstraZeneca PLC - Eli Lilly and Company - Otsuka Holdings Co., Ltd. - Sumitomo Chemical Company, Limited - Merck & Co., Inc. - Bristol-Myers Squibb Company - H. Lundbeck A/S - AbbVie Inc. - The University of Maryland - Yale University For more information visit http://www.researchandmarkets.com/research/pp...izophrenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Peptic Ulcers Global Clinical Trials Review, H2, 2013 Features the Key Drugs for Treating Peptic Ulcers
M2 - Wed Nov 20, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/p6twhl/peptic_ulcers) has announced the addition of the "Peptic Ulcers Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Peptic Ulcers Global Clinical Trials Review, H2, 2013" provides data on the Peptic Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peptic Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peptic Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Clinical Trial Overview of Takeda Pharmaceutical Company Limited - Pozen, Inc. - Clinical Trial Overview of Pozen, Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Zuventus Healthcare Ltd - Zeria Pharmaceutical Co Ltd - Otsuka Holdings Co., Ltd. - Eisai Co., Ltd. - Daiichi Sankyo Company, Limited - Chinese University of Hong Kong - Department of Health, South Africa - National Taiwan University Hospital - The Catholic University of Korea - Yokohama City University - Odense University Hospital - University of California, San Francisco - Keio University - Hamamatsu University School of Medicine - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/p6...tic_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
United States Supplement Market to 2016
M2 - Fri Oct 25, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rq7rxm/supplement_market) has announced the addition of the "United States Supplement Market to 2016" report to their offering. One of the main trends witnessed in the Supplement market in the US is the availability of supplement in alternate forms. Natural nutrients such as protein, vitamin, minerals, enzymes, and herbs and botanicals are important ingredients of the regular diet of a person. Proper consumption of these nutrients is essential for maintaining a healthy life. However, the presence of some adverse environmental factors, such as unhealthy diet and sedentary lifestyle are leading to malnutrition. Thus, with the introduction of supplement-based products, people are able to cope with these deficiencies. Vendors are providing supplement products in different forms such as instant health drinks, chocolate bars, probiotic drinks, pediatric nutrient products, adult nutrient products, and vitamin water. According to the report, one of the main factors driving the market is the increased focus on organic healthcare products. Organic healthcare products they are helpful in the treatment of diseases such cardiovascular, neurological diseases, and macular degeneration; effective against age-related muscular degeneration, and relieving cold and flu symptoms, which is in turn increasing demand for the same. Further, the report states that one of the main challenges is the negative publicity by media. But overly negative publicity against some of the supplement-based products by electronics media and print media is affecting consumer perception toward the supplement-based products. The key vendors dominating this space include: - Abbott Laboratories Inc. - GNC Holdings Inc. - NBTY Inc. - Otsuka Holdings Co. Ltd. - Perrigo Co. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology 05. Scope of the Report 06. Market Landscape 07. Vendor Landscape 08. Buying Criteria 09. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/rq...ent_market
Global Hyponatremia Clinical Trials Review Report, H2 2013 Edition
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2njzf6/hyponatremia) has announced the addition of the "Hyponatremia Global Clinical Trials Review, H2, 2013" report to their offering. Hyponatremia Global Clinical Trials Review, H2, 2013" provides data on the Hyponatremia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyponatremia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyponatremia. Reasons to Buy: - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Hyponatremia Therapeutics Clinical Trials - Astellas Pharma Inc. - Cardiokine, Inc. - Otsuka Pharmaceutical Co., Ltd. - Sanofi - Otsuka Holdings Co., Ltd. - Otsuka Pharmaceutical Development & Commercialization, Inc. - Otsuka Maryland Medicinal Laboratories, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Zydus Cadila Healthcare Limited - Ranbaxy Laboratories Limited For more information visit http://www.researchandmarkets.com/research/2n...ponatremia
Otsuka Pharmaceutical Co Ltd acquires Astex Pharmaceuticals for USD8.50 per share
M2 - Mon Oct 14, 5:50AM CDT
Otsuka Holdings Co Ltd reported on Friday the completion of the acquisition of Astex Pharmaceuticals Inc (NasdaqGS:ASTX) for USD8.50 per share, net to the seller in cash, without interest and less any required withholding taxes.
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
Business Wire - Fri Oct 11, 7:31AM CDT
Otsuka Holdings Co., Ltd. ("Otsuka Holdings") announced today that its wholly-owned subsidiary, Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), successfully completed, through its wholly-owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") for US $8.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The acquisition was effected through a tender offer ("Tender Offer"), which was commenced on September 13, 2013, New York time and expired at 12:00 midnight, New York time at the end of October 10, 2013, followed by a merger on October 11, 2013.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"), concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka"). Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.
Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
(0)
(0)